|
|
|
Amazing Green Tea Health Benefits.
Green tea has been used as a medicine in China for at
least 4,000 years. It's benefits to human health have been
widely known and talked about ever since it was first
discovered. Legend says that green tea was discovered in
2737BC when...
Generic or Name Brand: Do You Really Need a Statin Drug?
In June 2006, insurers and government agencies will have the
opportunity to start using an inexpensive generic version of the
cholesterol-lowering drug Zocor instead of the more pricey
Lipitor.
Pfizer, which makes Lipitor, plans to use...
Hemophilia
Hemophilia is a hereditary disease that does not allow blood to clot properly. There are two known forms of Hemophilia which are known as Hemophilia A and Hemophilia B.
Hemophilia A is the most common type and people with this type of Hemophilia...
The Plant-Based Diet: Is Meat Good for You?
Copyright 2011 Mary Desaulniers
Imagine this scenario: your 12 month old baby is fussing because
it is past his feeding time. You warm up his bottle of regular
whole milk. No more infant formula. He looks healthy. You are
feeding him well...
What you need to know about hrt
As an individual ages he or she is gripped by many physical problems. These problems have different origins. But most of the age-old troubles are a consequence of weak functioning or one can say retirement of the internal organs of the body. So as...
|
|
| |
|
|
|
|
|
|
New Hope for Alzheimer's Treatment
New Hope for Alzheimer’s Treatment
By Boris Predovich, Covance Research Products
There is now widespread agreement among research scientists and medical professionals that Alzheimer’s Disease (AD) is a problem quickly growing to vast proportions. As the life expectancy of Americans continues to rise, increasing the percentage of the population over 65 years of age, so does the number of Alzheimer’s cases.
It is currently estimated that people over 65 years of age have a 10% chance of developing Alzheimer’s, while those over 85 have a 50% likelihood of developing AD, making it the leading cause of dementia among older people. Though the disease is associated primarily with memory loss, its effects also comprise a number of other severe disabilities, including changes in personality, disorientation, difficulty with speech and comprehension, and a lack of ability to move normally.
Consequently, most Alzheimer’s patients require a great deal of care, costing society close to $100 billion annually. According to Christian Fritze, Ph.D., Director of the Antibody Products Division at Covance Research Products, "The impact of Alzheimer's Disease on our society will only increase as our population ages. The prevalence of the disease and disabling effects on the patient are significant by themselves. In addition we are becoming increasingly aware of the far-reaching effects on families, care-giver networks and the economics of our health care system. The drive for progress towards effective treatments by the research and drug development community is growing stronger every day."
A New Consensus
But recent developments in the medical research community do provide some hope. During the last two years, there has been a growing consensus among Alzheimer researchers about the cause of Alzheimer’s disease, providing focus for scientists exploring the new treatment options.
The focus is on amyloid beta oligomers, a new wrinkle on an older hypothesis called the “amyloid cascade hypothesis”. Widespread acceptance of this new conclusion is something of a milestone in the history of Alzheimer’s research. As Dr. Fritze says, "The decades old quest for the causative agent in Alzheimer's Disease has recently focused on the precursors of amyloid plaques. These precursors are part of a bewildering array of processed (APP) Amyloid Precursor Protein) variants, Tau isoforms and secretase components that play a role in neuronal cytotoxicity and subsequent brain dysfunction.”
Amyloid plaques are sticky protein deposits in the brain containing amyloid beta peptide. Researchers have associated the buildup of this plaque with Alzheimer’s disease since its discovery in 1907. But despite the clear correlation, scientists were not sure what, exactly, spurred the onset of Alzheimer’s Disease.
The hypothesis that amyloid beta accumulation in the brain is the major cause of Alzheimer’s Disease1 has been the focus of much attention over the past decade. Although this hypothesis was the leading explanation for the cause of AD, it had several weaknesses. The most obvious problem with the theory was the fact that the buildup of amyloid beta peptides did not necessarily correspond with the severity of Alzheimer’s symptoms.
However, in 19982 and in 20023, researchers proposed that it was not the amyloid beta plaques themselves that were neurotoxic – and therefore the cause of Alzheimer’s – but rather precursors to amyloid beta plaques formed by smaller aggregates of amyloid beta. These new ideas are gaining widespread acceptance among the Alzheimer’s research community, creating a consensus that had not existed before.
This new focus provides one more spur to action for Alzheimer’s researchers, and underscores the need for further advancement. “The AD field demands sophisticated, highly-sensitive research
tools to track these components and quantitate the existence of monomeric, oligomeric and fibrillar amyloid forms present in the progression of Alzheimer's disease,” says Dr. Fritze.
Antibody Treatment
Two new studies, both released in October 20044, suggest that new treatment options may be on the horizon. The studies are the modification of one of two previous attempts using amyloid beta (Aβ) antibodies in the treatment of Alzheimer’s Disease. The previous attempts, though not successful, did at least suggest new courses of action in Alzheimer’s research and provided invaluable information for researchers.
In the first of the two previous attempts, researchers injected the antigen itself – pieces of the beta amyloid protein that makes up amyloid plaque – into mice, in the hopes that the injections would generate an immune (antibody) response against amyloid. Results were initially positive. The injected antigen produced Aβ antibodies and slowed the onset of the disease by decreasing Aβ levels. However, when tried on humans, the procedure led to meningoencephalitis (an inflammation of tissue around the brain) in some patients, and was therefore halted.
In the second attempt, a passive immunity therapy was tried in which antibodies to amyloid beta (not amyloid protein) were injected into mice, but hemorrhaging and inflammation ensued due to the high antibody doses required to be effective.
New Hope
But now there appears to be new hope for the use of antibodies as therapeutic agents for the treatment of Alzheimer’s patients. In the first of the two new studies that appeared in October conducted by the National Institute for Longevity Sciences, NCGG, and the Center for Neurological Diseases, Brigham & Women’s College, Harvard Institute of Medicine, researchers modified the first procedure. Concluding that the meningoenchaphalitis which occurred in some patients was caused by autoimmune T-cell activation, the researchers hoped to develop a vaccine that could minimize this T-cell activation while retaining the production of Aß antibodies. To accomplish this they created an oral vaccine that attached Aß DNA to an adeno-associated virus vector, which served to mitigate T-cell activation. Thus they were able to decrease Aß levels in the brains of the mice and yet not activate T-cells to the degree they had before, greatly reducing the risk of meningoencephalitis.
In the other new study, conducted at the University of Illinois at Chicago, researchers succeeded in making the passive immunity protocol much safer. This they accomplished by changing the point of entry for the Aß antibodies. Rather than injecting the antibodies into the body of the mice, as was done previously, antibody was injected directly into the brain of the mice. Because the antibodies were injected directly into the brain, smaller doses were needed, and side effects were minimized.
The results of the above studies, and the potential for further optimized immunization strategies may prove to be watershed events in the history of Alzheimer’s treatment.
Covance is a leading provider of innovative antibody products and custom antibody development services to the research community for Alzheimer’s disease. Visit www.Covance.com for more in-depth information and to view the suite of products for Alzheimer’s disease. Boris Predovich is Vice President of Immunology and Surgical Services at Covance Research Products.
Notes
1.J.A. Hardy, G.A. Higgins (1992), Science, 256:184-5.
2.M.P. Lambert et al (1998), Proc Natl Acad Sci, 95:6448-53.
3.D.M. Walsh et al (2002), Nature, 416:535-9.
4.Neelima B. Chauhan et al (2004), Journal of Neuroscience Research, 78, 5:732-741.
Hideo Hara et al (2004), Journal of Alzheimer’s Disease, 6, 5:483-488.
About the Author
writer
|
|
|
|
|
| National Library of Medicine - National Institutes of Health |
| Part of the National Institutes of Health, the National Library of Medicine offers access to health information for consumer, patient, and physicians ... |
| www.nlm.nih.gov |
|
| Health and Medical Information produced by doctors - MedicineNet.com |
| Doctor-produced health and medical information written for you to make informed decisions about your health concerns. |
| www.medicinenet.com |
|
| Medicine in the Yahoo! Directory |
| Collection of sites for health professionals, with sections on specific disciplines, organizations, continuing education, conferences, publications, ... |
| dir.yahoo.com |
|
| MedlinePlus Health Information from the National Library of Medicine |
| Health information from the National Library of Medicine. Easy access to Medline and Health topics, medical dictionaries, directories and publications. |
| medlineplus.gov |
|
| Medicine - Wikipedia, the free encyclopedia |
| Medicine is a branch of health science and the sector of public life ... The practice of medicine combines both science as the evidence base and art in the ... |
| en.wikipedia.org |
|
| Journal Home - Nature Medicine |
| Nature Medicine has a vacancy for a Locum Assistant Editor for six months. The position involves working in all aspects of the editorial process, ... |
| www.nature.com |
|
| The New England Journal of Medicine: Research & Review Articles on ... |
| The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial ... |
| content.nejm.org |
|
| eMedicine Clinical Knowledge Base |
| eMedicine features up-to-date, searchable, peer-reviewed medical journals, online physician reference textbooks, and a full-text article database in 62 ... |
| www.emedicine.com |
|
| Open Directory - Health: Medicine |
| the entire directory, only in Health/Medicine. Top: Health: Medicine (11429). Description · Medical Specialties (4888); Surgery (2265) ... |
| dmoz.org |
|
| the www virtual library biosciences medicine |
| www.ohsu.edu/cliniweb/wwwvl/ - Similar pages |
|
|
| Medicine - home |
| Bimonthly journal covering the latest results in clinical investigation relevant to hospital and office practice. |
| www.md-journal.com |
|
| Institute of Medicine |
| The Institute of Medicine serves as adviser to the nation to improve health. |
| www.iom.edu |
|
| ScienceDaily: Health & Medicine News |
| Medical Research News. Health news on everything from cancer to nutrition. Full-text, images, updated daily. |
| www.sciencedaily.com |
|
| Google Directory - Health > Medicine |
| Search only in Medicine Search the Web. Medicine. Health > Medicine, Go to Directory Home. Categories. Alternative Medicine (6308) Basic Sciences (66) ... |
| www.google.com |
|
| the world wide web virtual library biosciences medicine |
| www.mcb.harvard.edu/biopages/medicine.html - Similar pages |
|
|
| PLoS Medicine - A Peer-Reviewed Open-Access Journal |
| PLoS Medicine is a peer-reviewed, international, open-access journal published ... Every issue of PLoS Medicine contains a selection of readers' responses. ... |
| medicine.plosjournals.org |
|
| Medicine On-Line - Medicine Online -The International Medical Journal |
| Medicine Online - independent and peer reviewed journal published by Priory Medical Journals - priory.com. |
| www.priory.com |
|
| Entrez PubMed |
| PubMed is a service of the US National Library of Medicine that includes over 16 million citations from MEDLINE and other life science journals for ... |
| www.ncbi.nlm.nih.gov |
|
| Stanford University School of Medicine |
| Home Page of the Stanford University School of Medicine. |
| med.stanford.edu |
|
| Medicine OnLine |
| Meds.com offers medical information and education on cancer (lung cancer, colon cancer, breast cancer, leukemia) and HIV / AIDS for patients, ... |
| www.meds.com |
|
|